GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)-Reference-Cited by-同舟云学术

GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)

Published:2021-05-10 Issue:9 Volume:31 Page:795-808
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Li Huilan¹,Fang Yuanying²^ORCID,Guo Shuchun³,Yang Zunhua¹^ORCID

Affiliation:

1. College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, China

2. National Engineering Research Center for Manufacturing Technology of TCM Solid Preparation, Jiangxi University of Chinese Medicine, Nanchang, China

3. Medicinal Chemistry Department, Shanghai Jemincare Pharm Co., LTD, Shanghai, China

Funder

Jiangxi Provincial Department of Science and Technology

Education Department of Jiangxi Province

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2021.1921152

Reference85 articles.

1. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

2. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists

3. IDF diabetes atlas 9th edition, 2019. [cited 2020 Dec 20]. Available from: https://diabetesatlas.org/en/[Last

4. Diabetes area patent participation analysis – part II: years 2011-2016

5. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in small-molecule insulin secretagogues for diabetes treatment;Biomedicine & Pharmacotherapy;2024-09

2. New labdane diterpenoids from Alpinia galanga: A new type of GLP‐1 secretagogues targeting the PKA‐CREB and PI3K‐Akt signaling axes;Archiv der Pharmazie;2024-07-19

3. Liraglutide innovations: a comprehensive review of patents (2014–2024);Pharmaceutical Patent Analyst;2024-07-16

4. Discovery of Selective Proteolysis-Targeting Chimera Degraders Targeting PTP1B as Long-Term Hypoglycemic Agents;Journal of Medicinal Chemistry;2024-05-01

5. Terazosin, a repurposed GPR119 agonist, ameliorates mitophagy and β-cell function in NAFPD by inhibiting MST1-Foxo3a signaling pathway;2024-04-26